HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Atkins reborn

This article was originally published in The Tan Sheet

Executive Summary

Atkins Nutritionals has "emerged from bankruptcy" after completing its Chapter 11 reorganization in five months, the company announces Jan. 10. A new business strategy focuses on "convenient, portable and nutritious food products" for "healthy, active men and women," Atkins states. The firm will spend $40 mil. promoting the Advantage line of bars and shakes; an ad campaign launched Jan. 8 in People, Newsweek, U.S. News & World Report, Business Week, The New York Times, Life and Sports Illustrated. Atkins filed for bankruptcy in August (1"The Tan Sheet" Aug. 8, 2005, p. 10)...

You may also be interested in...



Atkins Announces Chapter 11 Filing, Plans to Widen Consumer Base

Atkins Nutritionals' new "brand plan" will refocus the marketing of its bars and shakes in an effort to reach a broader nutrition-conscious audience

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel